{
  "chapter": "Gynecology-Endometrial Carcinoma",
  "questions": [
    {
      "q_no": 1,
      "question": "A 50-year-old postmenopausal woman, non-obese, presents with complaints of irregular vaginal bleeding over the past two months. She reports no significant medical history except for using unopposed estrogen hormone replacement therapy (HRT) for the last five years Which condition, characterized by elevated estrogen levels alone, increases her risk of developing endometrial cancer?",
      "options": {
        "A": "Polycystic Ovary Syndrome (PCOS)",
        "B": "Combined estrogen-progestin hormone replacement therapy (HRT)",
        "C": "Type 2 diabetes mellitus",
        "D": "Endometrial hyperplasia"
      },
      "correct_answer": "D",
      "explanation": "endometrium to unopposed estrogen, which is a significant risk factor for developing endometrial cancer. It is an overgrowth of cells in the endometrium due to excess estrogen without the balancing effects of progesterone Endometrial Carcinoma Risk factors Protective factors Age (>50 yrs) Obesity Estrogen exposure Nulliparity Tamoxifen Family history Lynch syndrome BRCA1 & BRCA2 mutations Diabetes Hypertension Polycystic ovary syndrome (PCOS) Oral contraceptives Pregnancy and childbirth Regular exercise Healthy weight management LNS-IUS Polycystic Ovary Syndrome ( PCOS) (Option A) is characterized by hormonal imbalances, including elevated levels of androgens and estrogen due to anovulation. However, the primary mechanism linking PCOS to endometrial cancer is the hormonal imbalance leading to chronic anovulation and unopposed estrogen exposure rather than high estrogen levels alone. Hormone replacement therapy (Option B) that combines estrogen with progestin (a synthetic form of progesterone) is considered safer than estrogen alone in postmenopausal women. Progestin counteracts the estrogen's effect on the endometrium, reducing the risk of endometrial hyperplasia and cancer compared to unopposed estrogen therapy. Type 2 diabetes (Option C) is associated with insulin resistance and hyperinsulinemia, which can increase estrogen levels by decreasing the production of sex hormone-binding globulin (SHBG). The primary mechanism linking diabetes to endometrial cancer is thought to be related to obesity and insulin resistance rather than elevated estrogen levels. Reference: William's Gynaecology, 4th edition, page 699.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 2,
      "question": "A 45-year-old woman presents with complaints of irregular menstrual bleeding for the past 6 months. A biopsy confirms a diagnosis of endometrial hyperplasia with atypia. She has completed childbearing and desires definitive management. What would be the next best step for her?",
      "options": {
        "A": "Progestin therapy",
        "B": "Hysterectomy",
        "C": "Endometrial ablation",
        "D": "Observation with repeat biopsy in six months"
      },
      "correct_answer": "B",
      "explanation": "hyperplasia with atypia, particularly in postmenopausal women. For the women who have completed childbearing. It eliminates the risk of endometrial cancer. Types of Endometrial Carcinoma Condition Characteristics 1.Simple Hyperplasia Benign condition Increased growth of glandular cells Hormonal imbalance (estrogen excess) 2. Complex Hyperplasia without Atypia Benign condition Increased growth of glandular and stromal cells Hormonal imbalance (estrogen excess) 3.Atypical Complex Hyperplasia Pre-malignant condition Increased growth with atypical cells (abnormal nuclei) Potential progression to endometrial cancer 4.Carcinoma in Situ (Endometrial Intraepithelial Neoplasia) Pre-invasive stage of endometrial cancer Abnormal cells confined to the epithelial layer High risk of progressing to invasive cancer Treatment: For women in reproductive age (fertility desired) No cytological atypia: 1.Simple Continued high dose progestin therapy: Medroxyprogesterone 20-40 mg, 3 to 4 times/day continuous (Option A) Local Levonorgestrel - IUD 2.Complex Endometrial Sampling at an interval of 3-6 months. B. With cytological atypia: 1.Simple Continued high dose progestin therapy Local Levonorgestrel - IUD 2.Complex For women in post reproductive years (fertility not desired) 1. No cytological atypia Medical therapy as above or Hysterectomy (Laparotomy/ Laparoscopy) (Option B) 2. With cytological atypia C) Endometrial ablation , a minimally invasive procedure destroys the uterine lining and is suitable for women who wish to avoid hysterectomy but may not be appropriate in cases of complex endometrial hyperplasia without atypia due to the risk of missing underlying cancerous changes. D) Observation with repeat biopsy in six months may be considered if there is an absence of cytologic atypia. Reference: 1. William's Gynaecology, 4th edition, pages 700, 701, 702, 703, 704 2. Treatment",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 3,
      "question": "Which statement regarding Type 1 and Type 2 endometrial cancer is correct?",
      "options": {
        "A": "Type 1 Endometrial CA is more aggressive and has a poor prognosis than Type 2",
        "B": "Type 1 Endometrial CA is associated with estrogen excess, in young & obese women",
        "C": "Type 2 Endometrial CA is typically low-grade and non-metastasized compared to Type 1",
        "D": "Type 2 Endometrial CA is often estrogen-dependent and associated with hyperplasia."
      },
      "correct_answer": "B",
      "explanation": "women young women, particularly those with obesity, there is an increased production of estrogen due to adipose tissue converting androgens into estrogen. This table summarizes the main differences between Type 1 and Type 2 endometrial cancer. Characteristic Type 1 Endometrial Cancer Type 2 Endometrial Cancer Incidence More common (80-85%) Less common (15-20%) Age at Diagnosis Younger (around 50s-60s) Older (postmenopausal women) Histology Endometrioid adenocarcinoma Serous carcinoma, clear cell carcinoma, carcinosarcoma Association with Hyperplasia Present Absent Estrogen Dependence Estrogen-driven; ER +ve Often estrogen-independent; HER 2 neu +ve Grade Typically low-grade and less aggressive Often high-grade and aggressive Prognosis Better Worst Metastatic Potential Less likely to metastasize More likely to metastasize Associated Mutation PTEN P53 Reference: William's Gynaecology, 4th edition, page 704",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 4,
      "question": "A 50-year-old woman presents with abnormal uterine bleeding. Endometrial biopsy reveals a histopathological diagnosis of endometrial carcinoma. Further evaluation shows that the tumor predominantly comprises glands with irregular architecture, cytologic atypia, and mitotic activity. What histopathological type of endometrial cancer does this description most likely correspond to?",
      "options": {
        "A": "Endometrioid carcinoma",
        "B": "Serous carcinoma",
        "C": "Clear cell carcinoma",
        "D": "Mucinous carcinoma"
      },
      "correct_answer": "A",
      "explanation": "atypia, and mitotic activity. It is the most common histopathological type of endometrial cancer . Endometrioid Carcinoma Serous carcinoma Clear cell carcinoma HPE Image Features Tubular glands with back to back pattern Eosinophilic keratin deposition May demonstrate cytological atypia (Option A) Complex papillae Free cells with significant cytological atypia (Option B) Hobnail cells with clear or eosinophilic cytoplasm. Nuclear Atypia seen (Option C) Prognosis Favourable Poorer Poorer D) Mucinous carcinoma of the endometrium is rare and characterised by glands filled with mucin.",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxobgy/Gynecology-Endometrial_Carcinoma_Q4_exp.jpg",
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 5,
      "question": "A 62-year-old postmenopausal woman presents with complaints of vaginal bleeding mixed with watery and offensive discharge for the past 4 weeks. Her last menstrual period was 10 years ago. Her medical history is significant for hypertension and obesity. Pelvic examination reveals a bulky uterus. Transvaginal ultrasound reveals an endometrial thickness of 14 mm. What is the most likely diagnosis?",
      "options": {
        "A": "Endometrial Carcinoma",
        "B": "Atrophic vaginitis",
        "C": "Endometrial hyperplasia",
        "D": "Cervical polyp"
      },
      "correct_answer": "A",
      "explanation": "Correct answer: A) Endometrial Carcinoma Explanation: Endometrial carcinoma is the most likely diagnosis given by the patient's postmenopausal status, vaginal bleeding with suspected pyometra(watery and offensive discharge), and an endometrial thickness greater than 4 mm on ultrasound. Endometrial CA is the most common gynecologic malignancy in postmenopausal women. Risk factors include obesity and hypertension, which are present in this patient. Symptoms: Menometrorrhagia ( irregular acyclic bleeding)- MC symptom in menstruating women Cyclical bleeding beyond the age of menopause Postmenopausal bleeding- MC symptom in postmenopausal women Pyometra- dirty foul-smelling vaginal discharge Obesity with DM & HTN Atrophic vaginitis (Option B) presents with thinning of vaginal epithelium due to decreased estrogen. It causes yellowish or blood-stained vaginal discharge, dyspareunia and dysuria but does not typically lead to significant endometrial thickening. Endometrial hyperplasia (Option C) : Causes abnormal uterine bleeding and endometrial thickening but never a pyometra which is present in this case. Considered a precursor to endometrial carcinoma, especially in the presence of risk factors like obesity and the presence of increased exogenous and endogenous estrogen levels. Cervical polyps (Option D) can cause irregular bleeding but are usually detected on pelvic examination and do not cause significant endometrial thickening. Reference: 1. Shaw’s Textbook of Gynecology, 17th Edition, Page 434, 435 2. Williams Gynecology, 4th Edition, Page 702, 705",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 6,
      "question": "A 58-year-old postmenopausal woman presents with complaints of intermittent vaginal bleeding for the past month. On pelvic examination, the cervix appears normal, and there is no palpable pelvic mass. A TVS reveals an endometrial thickness of 15 mm. What is the most appropriate next step to confirm the diagnosis of endometrial carcinoma in this patient?",
      "options": {
        "A": "Serum CA-125 level",
        "B": "MRI",
        "C": "Hysteroscopic endometrial biopsy",
        "D": "Fractional curettage(D&C)"
      },
      "correct_answer": "C",
      "explanation": "endometrial CA. It allows direct visualization of the uterine cavity and targeted biopsy of suspicious areas, providing an accurate histopathological diagnosis OPD procedure Done using Pipelle or a Sharman's curette A) Serum CA-125 level: Elevated levels (>35 IU/ml) can indicate advanced disease and help monitor therapy. They are more useful for follow-up rather than initial diagnosis. B) MRI can detect myometrial invasion, lymph node status, and endocervical spread. It is useful for women desiring fertility-sparing testing methods. (to exclude myometrial invasion). D) Fractional curettage(D&C) involves scraping the endometrium from different parts and all walls of the uterine cavity. While it can provide diagnostic tissue, it does not allow for direct visualization of the uterine cavity. Other Diagnostic Tools: Transvaginal ultrasonography (TVS) Endometrial thickness >4 mm Hyperechoic, irregular endometrium Increased vascularity with low resistance Intracavitary fluid. Pap smear Hysteroscopy CECT PET-CT Chest X-ray",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 7,
      "question": "A 68-year-old postmenopausal woman presents with abnormal vaginal bleeding. An endometrial biopsy confirms Endometrial CA. An MRI of the pelvis reveals that the tumor invades the cervical stroma but does not extend beyond the uterus. There is no evidence of lymph node involvement or distant metastasis. Based on the FIGO staging system, what is the stage of this patient's Endometrial CA?",
      "options": {
        "A": "Stage IA",
        "B": "Stage IB",
        "C": "Stage II",
        "D": "Stage IIIA"
      },
      "correct_answer": "C",
      "explanation": "without extending beyond the uterus. A) Stage IA: The tumor is confined to the endometrium & invades less than half of the myometrium. B) Stage IB: The tumor invades more than half of the myometrium. D) Stage IIIA: The tumor invades the uterine serosa and/or adnexa. FIGO STAGING OF ENDOMETRIAL CANCER (2023) STAGE DESCRIPTION I Confined to the uterine corpus and ovary IA Confined to endometrium; invasion of <50% of myometrium IB Confined to endometrium; invasion of >50% of myometrium IC Confined to the endometrium; Aggressive histological types limited to a polyp II Cervical stromal invasion IIA Non-aggressive histological types IIB Substantial LVSI (lymphovascular space involvement) of non-aggressive histological types IIC Aggressive histological types with any myometrial involvement III Local and/or regional spread of the tumor IIIA Invasion of uterine serosa &/or adnexa IIIB Vagina &/or the parametria or pelvic peritoneum involved IIIC Pelvic &/or para-aortic lymph nodes involvement IV Spread to the bladder mucosa &/or intestinal mucosa &/or distance metastasis IVA Invasion of the bladder mucosa and/or the intestinal/bowel mucosa IVB Abdominal peritoneal metastasis IVC Distant metastasis, including metastasis to any extra- or intra-abdominal lymph nodes above the renal vessels, lungs, liver, brain, or bone",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 8,
      "question": "A 55-year-old postmenopausal woman presents with abnormal uterine bleeding. An endometrial biopsy is performed, and the histopathological examination (HPE) report shows the presence of endometrial carcinoma with 40% solid areas. According to the FIGO grading system, what is the grade of this tumor?",
      "options": {
        "A": "Grade I",
        "B": "Grade II",
        "C": "Grade III",
        "D": "Unable to determine without additional information"
      },
      "correct_answer": "B",
      "explanation": "Endometrial CA is characterized by having 6-50% solid areas on HPE. FIGO Grading based on solid areas on HPE (Differentiation of cancer) Grade Description I ≤ 5% solid areas Well-differentiated (low-grade) tumors. II 6-50% solid areas Moderately-differentiated (intermediate-grade) tumors. III >50% solid areas Poorly-differentiated (high-grade) tumors. D) Unable to determine without additional information: The grade can be determined based on the provided information about the percentage of solid areas, which aligns with the criteria of the FIGO grading system. Reference: Williams Gynecology, 4th edition , Pages 707,716",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 9,
      "question": "All of the following are poor prognostic variables in endometrial cancer, except:",
      "options": {
        "A": "Clear cell adenocarcinoma",
        "B": "Older age",
        "C": "Advanced surgical stage",
        "D": "Endometrioid adenocarcinoma."
      },
      "correct_answer": "D",
      "explanation": "early due to its tendency to cause abnormal uterine bleeding, leading to timely diagnosis and treatment. These tumours are usually well differentiated, contributing to a favourable prognosis compared to other types of endometrial cancer that may exhibit more aggressive behaviour and poorer outcomes. Poor Prognostic Variables in Endometrial Cancer Advanced surgical stage (Option C) Older age (Option B) Aggressive histologic types: Uterine papillary serous carcinoma (UPSC), clear cell adenocarcinoma, or carcinosarcoma (Option A) High tumour grade Myometrial invasion Lymphovascular space invasion Positive peritoneal cytology Tumor size >2cm Reference: 1. Williams Gynecology, 4th edition, Page 716 2. Shaw’s Textbook of Gynaecology, 17th edition, Page 434",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 10,
      "question": "A 62-year-old woman diagnosed with endometrial carcinoma underwent a hysterectomy and lymph node sampling. Postoperative staging revealed the cancer to be at stage II. What is the next best step in her treatment?",
      "options": {
        "A": "Chemotherapy",
        "B": "Brachytherapy",
        "C": "External Beam Radiotherapy",
        "D": "Hormonal Therapy"
      },
      "correct_answer": "C",
      "explanation": "control local spread and improve outcomes. A) Chemotherapy : While chemotherapy is used for advanced stages (III or IV) or high-risk features, it is not typically the first step for stage II endometrial cancer B) Brachytherapy : This form of radiotherapy is often used for local control in the vaginal vault, especially in early-stage endometrial cancer (Stage 1), but it is generally not sufficient as a standalone treatment for stage II disease. D) Hormonal therapy - Hormonal therapy, such as high-dose progestogens, is used in advanced cases of endometrial cancer, particularly in patients with Stage III/IV, who cannot undergo surgery. However, it is not the standard treatment for stage II disease. Stage Treatment IA (non-invasive Surgery alone IA Surgery Post-op radiotherapy IB Surgery Post-op pelvic radiotherapy Post-op vaginal vault radiotherapy II Surgery Post-op external beam radiotherapy (whole abdomen irradiation) Radical total hysterectomy III Inoperable/Cytoreduction Chemotherapy Progesterone Therapy IV Inoperable/Cytoreduction Palliative Radiotherapy/Chemotherapy/Progesterone Therapy Reference: 1. Williams Gynecology, 4th edition, Page 714 2. Shaw’s Textbook of Gynaecology, 17th edition, Page 438",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 11,
      "question": "What is the most common site of recurrence of endometrial cancer?",
      "options": {
        "A": "Liver",
        "B": "Stomach",
        "C": "Upper Vagina",
        "D": "Lungs"
      },
      "correct_answer": "C",
      "explanation": "Liver can be sites for distant metastases in endometrial cancer, especially in advanced stages, but they are not the most common site of recurrence. (A, D) B) Stomach: It is usually not involved in the recurrence of endometrial cancer. Postoperative vaginal vault radiotherapy reduces the likelihood of recurrence. The treatment options for recurrence include progestogen therapy (5-10 mg daily), palliative chemotherapy, and radiotherapy if the patient has not received prior irradiation. Reference: 1. Williams Gynecology, 4th edition, Page 717. 2. Shaw’s Textbook of Gynaecology, 17th edition, Page 438.",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxobgy/Gynecology-Endometrial_Carcinoma_Q11_exp.jpg",
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    },
    {
      "q_no": 12,
      "question": "What is the most common cause of postmenopausal uterine bleeding in Western countries?",
      "options": {
        "A": "Endometrial polyps",
        "B": "Estrogen replacement therapy",
        "C": "Endometrial atrophy",
        "D": "Endometrial hyperplasia"
      },
      "correct_answer": "C",
      "explanation": "60% to 80% of cases. It results from the thinning of the endometrial lining due to decreased estrogen levels after menopause. Causes of postmenopausal bleeding % Of cases Endometrial Atrophy 60-80 Hormone Replacement Therapy 15-25 Endometrial Polyps 2-12 Endometrial Hyperplasia 5-10 Endometrial Cancer 10 A) Endometrial polyps account for 2% to 12% of cases of postmenopausal uterine bleeding. They are often difficult to identify with office procedures and may require hysteroscopy or transvaginal ultrasonography for accurate diagnosis. B) Estrogen replacement therapy increases the risk of endometrial hyperplasia and cancer but is not the most common cause. D) Endometrial hyperplasia is characterized by an overgrowth of the endometrial lining due to prolonged exposure to estrogen without progesterone which presents as postmenopausal bleeding. Carcinoma Cervix is the most common cause of postmenopausal uterine bleeding in India. Reference: 1. Causes of PMB 2. Berek & Novak's Gynecology, 16th Edition",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Gynecology-Endometrial Carcinoma"
    }
  ]
}
